BLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioLine RX Ltd (BLRX) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The lack of significant positive catalysts, weak financial performance, and absence of strong trading signals suggest holding off on this stock for now.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 64.693, and moving averages are converging, showing no clear trend. The stock is trading near its resistance levels (R1: 2.46, R2: 2.538), suggesting limited immediate upside potential.
Gross margin increased significantly to 79.38%, up 64.79% YoY, indicating operational efficiency.
No recent news or significant insider or hedge fund activity. Stock trend analysis predicts a -5.5% decline in the next month.
In Q4 2025, revenue dropped significantly to $194,000 (-98.35% YoY), and net income fell to -$2,236,000 (-29.84% YoY). Despite gross margin improvement, overall financial performance is weak.
No recent analyst ratings or price target changes available.
